Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Specific killing of P53 mutated tumor cell lines by a cross-reactive human HLA-A2-restricted P53-specific CTL line.

International journal of cancer - 1 Sept 2001

Würtzen P A, Pedersen L O, Poulsen H S, Claesson M H

Abstract excerpt

p53 is upregulated in the majority of spontaneous tumors and the HLA class I molecule HLA-A2 is expressed by approximately 50% of the caucasians. Potentially, these facts make HLA-A2-binding p53 peptides for CTL-inducing immunotherapy applicable to a broad range of cancer patients. In our study, we investigated the CTL-inducing capacity of autologous monocyte-derived dendritic cells (DC) maturated by exposure to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CD4-Positive T-Lymphocytes
Share to CD8-Positive T-Lymphocytes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dendritic Cells

Share to Epitopes

Share to Genes, p53

Share to HLA-A2 Antigen

Share to Peptides

Share to T-Lymphocytes, Cytotoxic

Source

Identifiers

PMID: 11519048
DOI: 10.1002/ijc.1417

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Specific killing of P53 mutated tumor cell lines by a cross-reactive human HLA-A2-restricted P53-specific CTL line.PMID 11519048Read ↗

A HLA-A2 restricted human CTL line recognizes a novel tumor cell expressed p53 epitope.Semantic proximity Read ↗

In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53.Semantic proximity Read ↗

Generation of cytotoxic T cell responses to an HLA-A24 restricted epitope peptide derived from wild-type p53Semantic proximity Read ↗

Cytotoxic T-lymphocyte clones, established by stimulation with the HLA-A2 binding p5365-73 wild type peptide loaded on dendritic cells In vitro, specifically recognize and lyse HLA-A2 tumour cells overexpressing the p53 protein.Semantic proximity Read ↗

Targeted tumor cell death induced by autologous tumor-specific T lymphocyte recognition of wild-type p53-derived peptides.Semantic proximity Read ↗

Tolerance to p53 by A2.1-restricted Cytotoxic T LymphocytesSemantic proximity Read ↗

Spontaneous human squamous cell carcinomas are killed by a human cytotoxic T lymphocyte clone recognizing a wild-type p53-derived peptide.Semantic proximity Read ↗

Generation of T cells specific for the wild-type sequence p53(264-272) peptide in cancer patients: implications for immunoselection of epitope loss variants.Semantic proximity Read ↗

CD8 T-cell responses against cyclin B1 in breast cancer patients with tumors overexpressing p53.Semantic proximity Read ↗

Targeting p53 as a general tumor antigen.Semantic proximity Read ↗

Wildtype p53-specific antibody and T-cell responses in cancer patients.Semantic proximity Read ↗

A wild-type sequence p53 peptide presented by HLA-A24 induces cytotoxic T lymphocytes that recognize squamous cell carcinomas of the head and neck.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.